Clinical Trials Browser

Interventional × Denosumab × 90 days × Clear all

NCT02833610 2026-02-18

A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency

Phase 2 Completed

Multiple Myeloma

NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

Phase 2 Completed

20 enrolled 8 charts

Smoldering Multiple Myeloma

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms